NEW YORK (GenomeWeb News) – Startup biotech firm KellBenx today announced it has raised $2.5 million in an initial funding round.
Four investors participated in the round, three undisclosed venture capital groups and an undisclosed angel investor.
"The funds will be used to launch an [institutional review board]-approved clinical trial and build our Long Island laboratory to analyze the data we are producing," Hassan Bennani, CEO of KellBenx, said in a statement.
Earlier this week, the company announced it had licensed three interleukin biomarkers from Cedars-Sinai Medical Center for the development of tests to predict premature births. The test will be in an ELISA format, but Bennani said that the company is considering next-generation sequencing technologies as well.